Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, a potential treatment for non-small cell lung cancer patients with the EGFR exon 21 L858R mutation. The lead Taiwan site is now open to accrual and actively screening patients, with additional IRB approvals anticipated at two more sites in the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying eligible patients. These developments matter because they signal progress in a trial that targets a specific genetic mutation associated with poor response to standard tyrosine kinase inhibitor therapy, potentially offering a new option for patients who have progressed after TKI treatment.
The amended protocol for Part 2 allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, an increase from the previous six cycles. This change is based on preliminary data showing a median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the extended treatment duration could potentially deepen responses and extend survival for this difficult-to-treat population. If the trial confirms these early signals, LP-300 could become a much-needed targeted therapy for L858R patients, who often have inferior outcomes compared to those with other EGFR mutations.
Lantern Pharma's approach leverages its proprietary RADR artificial intelligence and machine-learning platform, which integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies. This AI-driven strategy not only aims to improve clinical trial success rates but also to reduce the cost and time of drug development—a critical need in oncology, where many promising candidates fail late-stage testing. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The Taiwan approvals and U.S. progress could accelerate enrollment and generate data that might support regulatory submissions, potentially bringing LP-300 to market faster.
For investors, the news highlights Lantern's ability to execute on its clinical strategy and expand its trial footprint internationally, which can mitigate risks associated with slow enrollment. The latest updates and press releases relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN, and the full press release can be viewed at https://ibn.fm/CqeDR. BioMedWire, a specialized communications platform for the biotech and life sciences sectors, is part of the Dynamic Brand Portfolio at IBN and provides editorial syndication to 5,000+ outlets and social media distribution. More information about Lantern Pharma is available at Lantern Pharma (NASDAQ: LTRN).
